Payment overview · 2025
General Payments
$503.11
30 reported records · 11 companies
Healthcare provider profile · identity verified
Marion K. Studebaker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · YUKON, OK · NPI 1306875729
Verified facts
What the public records show
CMS Open Payments records show Marion K. Studebaker, M.D. received $503.11 in general payments during 2025 across 30 reported records.
PFIZER INC. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $157.25 | 31.3% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $79.23 | 15.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.83 | 12.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.15 | 10.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.27 | 8.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.14 | 5.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.19 | 4.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.16 | 3.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.27 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.00 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.62 | 2.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $503.11 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $120.39 | 8 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $120.39 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $120.39 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $84.95 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $79.23 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.14 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.62 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 614 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 87 |
| Lisinopril | Lisinopril | 285 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 78 |
| Alprazolam | Alprazolam | 220 | 37 |
| Losartan Potassium | Losartan Potassium | 210 | 63 |
| Metformin Hcl | Metformin Hcl | 203 | 60 |
| Gabapentin | Gabapentin | 179 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 52 |
| Simvastatin | Simvastatin | 149 | 40 |
| Omeprazole | Omeprazole | 145 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 45 |
| Allopurinol | Allopurinol | 129 | 38 |
| Potassium Chloride | Potassium Chloride | 122 | 41 |
| Trazodone Hcl | Trazodone Hcl | 122 | 40 |
| Montelukast Sodium | Montelukast Sodium | 120 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 28 |
| Furosemide | Furosemide | 100 | 36 |
| Meloxicam | Meloxicam | 96 | 31 |
| Tramadol Hcl | Tramadol Hcl | 94 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 27 |
| Ezetimibe | Ezetimibe | 87 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 22 |
| Jardiance | Empagliflozin | 73 | 17 |
| Eliquis | Apixaban | 69 | 20 |
| Ozempic | Semaglutide | 68 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 22 |
| Celecoxib | Celecoxib | 65 | 22 |
| Alendronate Sodium | Alendronate Sodium | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 64 | 13 |
| Clonidine Hcl | Clonidine Hcl | 63 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 20 |
| Sertraline Hcl | Sertraline Hcl | 63 | 17 |
| Finasteride | Finasteride | 59 | 20 |
| Cephalexin | Cephalexin | 57 | 51 |
| Glimepiride | Glimepiride | 57 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 57 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 18 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 38 |
| Carvedilol | Carvedilol | 43 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 13 |
| Azelastine Hcl | Azelastine Hcl | 38 | 15 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Famotidine | Famotidine | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Doxepin Hcl | Doxepin Hcl | 29 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 26 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $503.11 · 30 records | PFIZER INC. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error